globulin: a report of three patients and review of the liter- ature. Br J Dermatol 2000;142:551-554. 11. Wakim M, Alazard M, Yajima A, Speights D, Saxon A, Stiehm ER. High dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome. Ann Allergy Asthma Immunol 1998;81:153-158. 12. Jolles S, Sewell C, Webster D, Ryan A, Heelan B, Waite A, et al. Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytokine levels and CD4 counts. Acta Derm Venereol 2003;83:433-437. 13. Enk A; European Dermatology Forum Guideline Subcom- mittee. Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. Eur J Dermatol 2009;19: 90-98. 14. Paul C, Lahfa M, Bachelez H, Chevret S, Dubertret L. A IVIG Monotherapy in Resistant Atopic Dermatitis of a Child randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. Br J Dermatol 2002;147:518-522. 15. Gelfand EW. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol 2006;6:592-599. 16. Jolles S, Hughes J, Whittaker S. Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol 1998;134:80-86. 17. Jolles S, Hughes J, Rustin M. Intracellular interleukin-4 pro- files during high-dose intravenous immunoglobulin treat- ment of therapy-resistant atopic dermatitis. J Am Acad Der- matol 1999;40:121-123. 18. Grewe M, Bruijnzeel-Koomen CA, Schöpf E, Thepen T, Langeveld-Wildschut AG, Ruzicka T, et al. A role for Th1 and Th2 cells in the immunopathogenesis of atopic der- matitis. Immunol Today 1998;19:359-361. Vol. 24, No. 1, 2012 69